Milrinone

Milrinone is a medication used to help the heart pump blood more effectively. It's often used for people who have heart problems and need extra support. It works by relaxing blood vessels and making the heart muscle stronger.

Brand names:Primacor
Medication

What people taking Milrinone report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Milrinone

What It's For

Milrinone is an intravenous heart medicine used when heart failure suddenly worsens and the heart can no longer pump enough blood to meet the body's needs. In the US it is approved for short-term treatment of acute decompensated heart failure, meaning a flare in which fluid builds up and organs start to receive too little blood despite usual treatment. It was once sold under the brand name Primacor, which has been discontinued; it is now supplied as generic milrinone. Milrinone belongs to a group called inotropes, medicines that strengthen the heart's squeeze. Because it also relaxes blood vessels, it is sometimes called an inodilator. It is a hospital medicine given to people who are seriously ill, not a routine treatment for stable heart failure. Some people with advanced heart failure keep receiving milrinone through a long-term IV line at home. This is done either to keep them stable while they wait for a heart transplant or a left ventricular assist device (LVAD, an implanted heart pump), or as palliative care to ease symptoms when those options are not possible. Heart failure guidelines support inotropes as a bridge to transplant or an LVAD, while long-term home use for palliation carries a weaker recommendation because the evidence comes mainly from observational studies.

How It Works

Inside heart and blood vessel muscle cells, a chemical messenger (cAMP) helps control how strongly the heart contracts and how relaxed the vessel walls are. An enzyme called phosphodiesterase-3 (PDE3) normally breaks this messenger down. Milrinone blocks PDE3, so the messenger builds up. In the heart, this makes each beat more forceful and helps the muscle relax between beats. In the blood vessels of the body and the lungs, it widens the vessels, which lowers the resistance the heart pumps against. Together, these effects raise the amount of blood pumped each minute and lower the pressures that cause fluid to back up into the lungs. Most people's circulation measurements improve within 5 to 15 minutes of starting. Milrinone works differently from dobutamine, another common inotrope that acts on beta receptors. Beta-blockers occupy those same receptors and can blunt dobutamine, but milrinone acts further along the pathway, so it can still work in people taking beta-blockers.

Dosage & Administration

Milrinone is given only by vein, by a nurse or through a programmed infusion pump. In the hospital, treatment often starts with a loading dose given slowly over about 10 minutes, followed by a continuous infusion. The dose is calculated from body weight and adjusted according to blood pressure, heart rhythm and how well circulation improves. The kidneys clear milrinone from the body, so the infusion rate is reduced for people with reduced kidney function to keep the drug from building up. Effects fade over several hours after the infusion stops, which also means a problem can last for a while if the drug has accumulated. For home use, milrinone runs continuously through a long-term IV catheter, such as a peripherally inserted central catheter (a thin line placed through an arm vein) or a tunneled central line, using a portable pump. A home infusion pharmacy and nurse supply the medicine and look after the line, and the dose is set by the heart failure team rather than changed at home.

Side Effects

The most important side effects involve the heart's rhythm. Extra or irregular heartbeats from the lower chambers (ventricular arrhythmias) occurred in about 12% of people in the main clinical trials, and rarely these can be dangerous. Faster rhythms in the upper chambers, including atrial fibrillation, also occur. Low blood pressure is the other main effect, which can cause dizziness or lightheadedness; the team slows or stops the infusion if pressure falls too far. Headache, usually mild, and chest pain are less common. People on home milrinone face additional risks from the long-term line itself, especially bloodstream infection. Fever, chills, or redness, swelling, pain or drainage where the line enters the skin should be reported to the heart failure or infusion team right away, as should a pump alarm or a stopped infusion, because losing the medicine suddenly can make heart failure worse quickly. A racing or pounding heartbeat, new dizziness or a shock from an implanted defibrillator (a device that shocks the heart out of a dangerous rhythm) also needs a prompt call to the team. Fainting, or a defibrillator shock followed by feeling unwell, needs emergency care.

Interactions & Warnings

Milrinone's safety record is limited to short-term use. In controlled trials, no one received it for more than 48 hours, and a large trial of long-term oral milrinone in people with moderate to severe heart failure found more hospital stays and more deaths, with no improvement in symptoms. The oral form was never marketed. Long-term home infusion is therefore a deliberate trade-off made for people with advanced heart failure, accepting rhythm and infection risks for better circulation and symptom control, and it is not assumed to extend life. The label cannot rule out a similar risk with long-term infusion, although newer observational series in people on modern heart failure treatment have not shown it clearly. A trial of routine short-term milrinone in people hospitalized for worsening heart failure who did not clearly need an inotrope found no reduction in time spent in hospital, along with more low blood pressure and atrial arrhythmias. For that reason it is reserved for people whose circulation is genuinely failing. Low potassium raises the risk of rhythm problems, so potassium is checked and corrected before and during treatment, especially in people taking digoxin (Lanoxin, an older heart medicine that slows the heart rate and supports pumping) or strong diuretics (water pills, which can lower potassium). Milrinone can speed the heart rate in atrial fibrillation or flutter that is not well controlled. It is not recommended right after a heart attack, and it does not replace surgery for a severely narrowed aortic or pulmonary valve. It should not be used by anyone who has had an allergic reaction to it. Its safety in pregnancy and in children has not been established in controlled studies.

What to Expect

In the hospital, milrinone is given with continuous heart-rhythm monitoring and frequent blood pressure checks, usually in an intensive care or cardiac unit. Blood tests track kidney function and potassium. As circulation improves, people often make more urine and may need less diuretic. Once the heart failure is stabilized, the team usually tapers and stops the infusion and moves to oral heart failure medicines. When milrinone continues at home, life involves carrying a small pump, protecting the IV line, and regular visits or blood tests with the heart failure team. For those waiting for a transplant or an LVAD, the goal is to stay well enough to get there. For those receiving it as palliative care, the aim is fewer hospital stays and more comfortable days, and survival has varied widely between studies, with one observational series reporting about half of these patients alive at one year. Planning with the care team about goals and what happens if the infusion stops is part of this care.

Questions to Ask Your Doctor

  1. 1.Why is milrinone the right inotrope for me rather than dobutamine, and how will we know it is working?
  2. 2.How long do you expect me to need the infusion, and what is the plan for stopping it?
  3. 3.If I go home on milrinone, what does caring for the line involve, and who do I call about fever, line problems or a defibrillator shock?
  4. 4.Is home milrinone a bridge to a transplant or LVAD for me, or is it meant to ease symptoms, and what does that mean for my other treatment choices?
  5. 5.How will my kidney function and potassium be checked while I am on it?

Last reviewed • Oct 2026

Educational content, not medical advice.